Continuous hematopoietic cell lines have become important research tools, contributing significantly to a better understanding of the pathophysiology of hematopoietic tumors. 1, 2 A relatively large number of cell lines have also been derived from patients with multiple myeloma and related diseases such as plasma cell leukemia, plasmacytoma, etc. 3, 4 Unfortunately, a high percentage of hematopoietic cell lines seem to have been cross-contaminated with cells from other cell lines, which, as they have a growth advantage, overgrew completely the original culture. 5 Cell line Jijoye was established from the tumor tissue of a 7-year-old boy with Burkitt lymphoma in Africa in 1963. 6, 7 The cell line HS-Sultan was allegedly established from the plasmacytoma of a 56-year-old Caucasian man who had IgG multiple myeloma. 8 In a recent study by Davies et al (and also in a large number of previous studies by this group), the continuous cell line HS-Sultan was used as a "multiple myeloma" cell line. 9 However, it has been clearly established that this cell line is in reality a subclone of the Burkitt lymphoma-derived cell line Jijoye and not a myeloma cell line. 3, 8, 10, 11 The evidence is 5-fold: most importantly DNA fingerprinting, but also viral, cytogenetic, immunologic, and morphologic findings. Due to insufficient documentation of the allegedly "new" cell line and hence caused by the lack of a proper karyotype of the original HS-Sultan cells, the circumstances of the crosscontamination can no longer be traced back. Most likely, during the attempts to establish a cell line, the cell culture was crosscontaminated with Jijoye cells, so there probably never was an "individual" HS-Sultan.
DNA fingerprinting using different methodologic approaches at the cell line banks American Type Culture Collection (ATCC) and the German Collection of Microorganisms and Cell Cultures (German abbreviation DSMZ) document independently and unequivocally that cell lines HS-Sultan and Jijoye carry identical DNA fingerprints (Figure 1) .
Both Jijoye and HS-Sultan are Epstein-Barr virus-positive (EBV ϩ ). 8 While all African-type Burkitt lymphomas are EBV ϩ (including the cell lines derived from these tumors), myeloma is clearly not an EBV-associated disease; neither EBV DNA nor EBV nuclear antigen (EBNA) have been detected in myeloma cells in the tumor. Myeloma cells are usually refractory to EBV immortalization. There is no bona fide EBV ϩ myeloma cell line. 4 Our cytogenetic analysis showed that both Jijoye and HS-Sultan have a similar though not identical hyperdiploid karyotype including t(8;14)(q24;q32), occurring in 75%-85% of all Burkitt lymphoma cases, 12 together with partial or complete trisomy of chromosome 7. Their karyotypes are as follows: Jijoye, 46/47͗2n͘X/ XY,dup(7)(q35q36),t(8;14)(q24;q32),der(14)t(9;14)(q11;q32), Ϫ18,ϩ2mar; and HS-Sultan, 48͗2n͘XY,ϩ7,t(8;14)(q24;q32), ϩmar. EBV is, of course, a polyclonal activator and any karyotypic differences may be either in vitro artefacts or attributable to the known propensity of Jijoye to give rise to phenotypically distinct subclones or a combination of both. It should be mentioned that the t(8;14)(q24;q32) is not specific for Burkitt lymphoma and was also found in some 6% of the bona fide myeloma cell lines. 4 A comparative immunophenotyping analysis of myeloma and nonmyeloma cell lines showed that HS-Sultan does not express a immunomarker profile compatible with that of canonical myeloma cell lines. 4, 10 Finally, on May-Grünwald-Giemsa-stained cytospin slides, HSSultan cells do not display the morphologic features that are typical of myeloma cell lines (deep basophilic cytoplasm, excentrically located nucleus, perinuclear clear hof, dense or clumped chromatin). On the contrary, HS-Sultan cells show an abundance of vacuolization (typical for B-acute lymphoblastic leukemia and Burkitt lymphoma, also described as FAB L3), large nuclei and prominent nucleoli.
Cross-contamination of cell lines is a wide-spread problem and invalidates many research results. 13 DNA fingerprinting, which is the method of choice, has documented that about 15%-20% of the currently "circulating" cell lines are cross-contaminated and overgrown by other cells. 5, 11 Unfortunately, cell line HS-Sultan had been used indiscriminately in a large number of studies (even after A multiple-locus DNA profile of the indicated cell lines was generated using 10 g of DNA digested to completion (HinfI), size-separated on agarose gels and blotted on positively-charged nylon membranes. After hybridization with a digoxigenin-labelled (GTG)5 oligonucleotide as probe, a chemoluminescent detection of (GTG)5 was carried out and the blot exposed for 15 minutes to X-ray films. Molecular weight markers were used for size determination. Cervix carcinoma cell line HELA was used as positive control. The methods used have been described in details elsewhere. 11, 13 13. 
To the editor:
Traumatic lumbar puncture at diagnosis and outcome in childhood acute lymphoblastic leukemia
The recent report by Gajjar et al 1 demonstrates impressively the adverse effect of a traumatic lumbar puncture (defined as more than 10 red blood cells per microliter of cerebrospinal fluid [CSF]) at the time of diagnosis on treatment outcome of children with acute lymphoblastic leukemia (ALL). The inferior prognosis can be predominantly observed in a subgroup of patients with 2 consecutive traumatic lumbar punctures and the detection of leukemic cells in the CSF. The authors conclude that the iatrogenic introduction of leukemic cells into the CSF may be one reason for the reduced outcome. In the treatment protocols XI 2 and XII 3 of the St Judes Children's Research Hospital, the patients received the first intrathecal therapy with methotrexate, hydrocortisone, and cytarabine at day 2. Thus they had a period of at least 24 hours without sufficient central nervous system (CNS)-directed treatment. In contrast, in ALL-Berlin-Frankfurt-Munich (BFM) frontline protocols, the first intrathecal methothrexate is immediately administered during the diagnostic lumbar puncture. Consecutive lumbar punctures (at diagnosis and for CNS-directed treatment), which may increase the risk of contamination of the CSF with blast cells, are not necessary. Furthermore, Gajjar et al's data show a surprisingly high percentage of traumatic punctures (21%), in more than half of the cases with detection of leukemic blasts in the CSF after cytocentrifugation. 1 From 88 children with initial ALL treated in our institution between November 1995 and January 2001, 56 CSF preparations of the diagnostic lumbar puncture had been preserved and the CNS status could be reevaluated. A traumatic lumbar puncture according to the above classification groups occurred in 4 out of 56 cases (7%), and in only 1 sample could 1 single leukemic cell be observed. Hitherto, 5 children suffered a leukemic relapse (3 isolated and 2 combined bone marrow/testis relapses). No CNS relapse occurred within this group.
These data emphasize the importance of a properly performed lumbar puncture particularly at time point of diagnosis when higher numbers of blast cells are circulating in the peripheral blood. Diagnostic lumbar punctures should only be done by an experienced physician. Furthermore, early administration of CNSdirected therapy might help to reduce the risk of blast cell microdissemination in the case of iatrogenic inoculation of blood during the procedure.
